Lymphoma  >>  Gazyva (obinutuzumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

44 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT02292225: Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Checkmark P1b SYNCHRONY trial of duvelisib + Gazyva in CLL/SLL
Jan 2017 - Jan 2017: P1b SYNCHRONY trial of duvelisib + Gazyva in CLL/SLL
Checkmark In patients previously treated with ibrutinib
Oct 2015 - Oct 2015: In patients previously treated with ibrutinib
Terminated
1b
3
Canada, US
IPI-145 (duvelisib), Duvelisib, Obinutuzumab, GAZYVA
SecuraBio
Lymphocytic Leukemia, Chronic, Lymphoma, Small Lymphocytic
11/16
11/16
NCT02417285: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Checkmark For r/rNHL (DLBCL, FL and MZL) at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: For r/rNHL (DLBCL, FL and MZL) at ASH 2017 [screenshot]
Checkmark In R/R DLBCL or iNHL at ASH 2016
Dec 2016 - Dec 2016: In R/R DLBCL or iNHL at ASH 2016
Completed
1b
75
Europe
Obinutuzumab, GA-101, CC-122
Celgene
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
05/19
09/23
NCT01644253: Phase 1b Safety and Efficacy Study of TRU-016

Hourglass Jan 2017 - Jun 2017 : From P1b trial (NCT01644253) in combination with Rituximab and Obinutuzumab in previously untreated CLL
Checkmark In combination with rituximab in pts with CLL
Dec 2013 - Dec 2013: In combination with rituximab in pts with CLL
Checkmark Presentation of data from TRU-016 + rituximab trial of expanded cohort and original cohort for first-line CLL
Nov 2013 - Nov 2013: Presentation of data from TRU-016 + rituximab trial of expanded cohort and original cohort for first-line CLL
Terminated
1b
87
US
20 mg/kg TRU-016 + Rituximab, Rituxan, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab, Gazyva, TRU-016 6-20 mg/kg + idelalisib + rituximab, Zydelig, Rituxan, TRU-016 10-20 mg/kg + ibrutinib, Imbruvica, TRU-016 10-20 mg/kg + bendamustine
Aptevo Therapeutics
Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
02/20
04/21
NCT04434196: A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Active, not recruiting
1b
50
Europe, Canada, US
CC-99282, Obinutuzumab
Celgene
Lymphoma, Non-Hodgkin
11/24
05/25
jRCT2080225077: A PHASE I STUDY OF RO7082859 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA

Completed
1
12
Japan
Columvi (glofitamab) - Roche, Gazyva (obinutuzumab) - Roche, Biogen, Nippon Shinyaku, Actemra IV (tocilizumab) - Roche, JW Pharma
Chugai Pharmaceutical Co., Ltd.
 
 
GALTON, NCT01300247: A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Checkmark Presentation of data from GALTON (GA 101+bendamustine combo & FC chemotherapy) trial in previously untreated chronic lymphocytic leukemia at ASH
Nov 2013 - Nov 2013: Presentation of data from GALTON (GA 101+bendamustine combo & FC chemotherapy) trial in previously untreated chronic lymphocytic leukemia at ASH
Completed
1
41
US
Fludarabine, Obinutuzumab, RO5072759; GA101, Bendamustine, Cyclophosphamide
Genentech, Inc.
Lymphocytic Leukemia, Chronic
01/13
12/15
NCT01680991: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Completed
1
48
RoW
Obinutuzumab, RO5072759, GA101
Hoffmann-La Roche
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
12/14
12/14
NCT02339181: A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Recruiting
1
70
US, Europe
GDC-0199 (ABT-199), Obinutuzumab
Hoffmann-La Roche, Accord Healthcare, Inc., AbbVie (prior sponsor, Abbott), Apotex Corporation, Alkem Laboratories Ltd
Lymphocytic Leukemia, Chronic
01/15
11/16
GAUDI, NCT00825149: A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Checkmark relapsed/refractory follicular lymphoma
Jul 2013 - Jul 2013: relapsed/refractory follicular lymphoma
Checkmark P1 data in FL
More
Completed
1
137
Europe, RoW
Bendamustine, Cyclophosphamide, Doxorubicin, Fludarabine, Obinutuzumab, RO5072759, Prednisone, Vincristine
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
11/15
11/15
NCT02100852: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

Checkmark TGR-1202 + Gazyva in CLL at ASH 2015
Dec 2015 - Dec 2015: TGR-1202 + Gazyva in CLL at ASH 2015
Completed
1
19
US
TGR-1202 + Obinutuzumab + Chlorambucil, Obinutuzumab: Gazyva, Chlorambucil: Leukeran
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
11/17
11/17
NCT01685892: A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Completed
1
82
Europe, US
Obinutuzumab, GA101; RO5072759, Venetoclax, ABT-199, GDC-0199
Genentech, Inc., AbbVie (prior sponsor, Abbott)
Lymphocytic Leukemia, Chronic
05/18
08/19
NCT01671904: A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Checkmark Venclexta +Gazyva + Rituxan +/- bendamustine in relapsed/refractory CLL at ASH 2016
Dec 2016 - Dec 2016: Venclexta +Gazyva + Rituxan +/- bendamustine in relapsed/refractory CLL at ASH 2016
Checkmark P1 data
Sep 2012 - Sep 2012: P1 data
Completed
1
84
Europe, US
Bendamustine, Obinutuzumab, GA101; RO5072759, Rituximab, MabThera; Rituxan, Venetoclax, ABT-199; GDC-0199
Genentech, Inc., AbbVie (prior sponsor, Abbott)
Chronic Lymphocytic Leukemia
08/18
08/20
NCT02336048: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Terminated
1
38
Europe, RoW
Chlorambucil, Obinutuzumab, RO5072759, GA101, Gazya, Gazyvaro, Placebo, Standard Premedication, Tocilizumab, RO4877533, RoActemra, Actemra
Hoffmann-La Roche
B-Cell Chronic Lymphocytic Leukemia
09/18
09/18
NCT03369964: A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Withdrawn
1
0
US
Atezolizumab, Emactuzumab, Obinutuzumab
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
12/18
08/19
NCT02453087: A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Completed
1
66
US
DCDS0780A, Rituximab, Rituxan®, MabThera®, Obinutuzumab, GA101, Gazyva™, Gazyvaro™
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
07/19
07/19
NCT02611908: Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Withdrawn
1
0
NA
ibrutinib, Imbruvica, obinutuzumab, Gazyva
Michael Choi, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia
11/19
11/20
NCT02220842: A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Checkmark Data from trial in combination with Tecentriq in r/r DLBCL at ICML 2019
Jun 2019 - Jun 2019: Data from trial in combination with Tecentriq in r/r DLBCL at ICML 2019
Checkmark Tazemetostat and Tecentriq in combination for r/r DLBCL
Jul 2016 - Dec 2016: Tazemetostat and Tecentriq in combination for r/r DLBCL
Checkmark EHA 2016
More
Completed
1
96
Europe, US
Atezolizumab, Tecentriq, Obinutuzumab, Tazemetostat, EPZ6438
Hoffmann-La Roche
Lymphoma
01/20
01/20
NCT02537613: A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Active, not recruiting
1
54
US
Obinutuzumab, Gazyva, GA-101, Ibrutinib, Imbruvica
Dana-Farber Cancer Institute, Genentech, Inc.
Chronic Lymphocytic Leukemia
03/20
01/29
SAKK 35/15, NCT02877550: Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Completed
1
25
Europe
Obinutuzumab, GA101, Gazyvaro, Gazyva, Venetoclax, ABT-199, GDC-0199, Venclexta
Swiss Group for Clinical Cancer Research
Follicular Lymphoma
04/20
05/22
CITADEL-102, NCT03039114: Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma

Completed
1
26
Europe, US, RoW
Parsaclisib, INCB050465, Hexal, Bendamustine, Gazyvaro, Gazyva®, Obinutuzumab
Incyte Corporation
Lymphoma
03/21
03/21
ACE-CL-003, NCT02296918: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Hourglass Jul 2022 - Dec 2022 : Data from trial for CLL/SLL/PLL
Checkmark From ACE-CL-003 trial in CLL/SLL/PLL
Jul 2021 - Jul 2021: From ACE-CL-003 trial in CLL/SLL/PLL
Checkmark Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Feb 2019 - Feb 2019: Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Active, not recruiting
1
69
US
acalabrutinib, ACP-196, Obinutuzumab, Gazyvaro, Venetoclax, ABT-199, Venclexta, GDC-0199, Rituximab, Rituxan
Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
08/21
09/27
GO41943, NCT04313608: A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Completed
1
23
RoW
Glofitamab, RO7082859, Gemcitabine, Oxaliplatin, Mosunetuzumab, RO7030816, Obinutuzumab, RO5072759, Tocilizumab, RO4877533
Hoffmann-La Roche
B-cell Lymphoma
10/21
10/21
VENOBI-CNS, NCT04073147: Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma

Terminated
1
4
Europe
Venetoclax, Venclyxto, Obinutuzumab, Gazyvaro
Klinikum Stuttgart, University Hospital Freiburg
Primary CNS Lymphoma
11/21
11/21
YO42610, NCT04657302: A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed
1
30
RoW
Obinutuzumab, Glofitamab, Tocilizumab
Hoffmann-La Roche
Lymphoma
10/22
01/24
NCT04245722: FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Terminated
1
98
US
FT596, Cyclophosphamide, Fludarabine, Rituximab, Rituxan, Truxima, Ruxience, Obinutuzumab, Gazyva, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
09/23
09/23
FT516-101, NCT04023071: FT516 in Subjects With Advanced Hematologic Malignancies

Terminated
1
72
US
FT516, Rituximab, Rituxan, MabThera, Obinutuzumab, Gazyva, Cyclophosphamide, Fludarabine, IL-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Acute Myelogenous Leukemia, B-cell Lymphoma
10/23
10/23
ISRCTN17975931: A study to evaluate the safety, tolerability, processing by the body, mechanism of action, and effectiveness of glofitamab following obinutuzumab pretreatment in patients with B-cell non-Hodgkin lymphoma

Recruiting
1
36
Australia, Belgium, Denmark, Italy, Poland, Spain, US
Gazyva (obinutuzumab) - Roche, Biogen, Nippon Shinyaku, Columvi (glofitamab) - Roche, dexamethasone - Generic mfg., Actemra IV (tocilizumab) - Roche, JW Pharma, Actemra SC (tocilizumab SC) - Roche, Halozyme
Genentech, Inc;Genentech, Genentech
B-cell non-Hodgkin lymphoma
 
 
NCT02992522: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Active, not recruiting
1
22
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Beth Christian, Celgene, Genentech, Inc.
B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, B-Cell
12/24
12/24
NCT06192888: A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Recruiting
1
39
US
Glofitamab, Obinutuzumab, Lenalidomide
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Mantle Cell Lymphoma, MCL
01/28
01/28
NCT05211336: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruiting
1
4
US
Obinutuzumab, Prednisone, Lenalidomide, Venetoclax, Ibrutinib
National Cancer Institute (NCI)
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
06/24
06/29
NCT04578600: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Active, not recruiting
1
8
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Oral Azacitidine, CC-486
Joseph Tuscano, National Cancer Institute (NCI), Celgene
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
04/24
12/24
NCT06291220: A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Not yet recruiting
1
80
NA
Obinutuzumab, ABBV-453
AbbVie
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
07/29
07/29
GO43693, NCT05364424: A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Recruiting
1
40
US
Glofitamab, Obinutuzumab, Tocilizumab, Rituximab, Ifosfamide, Carboplatin, Etoposide
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma (DLBCL)
12/24
12/24
NCT04739813: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Recruiting
1
55
US
obinutuzumab, prednisone, Revlimid, Polatuzumab, ibrutinib, venetoclax
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
07/24
07/29
NP40126, NCT03467373: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Checkmark Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Dec 2022 - Dec 2022: Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Active, not recruiting
1
172
Europe, Canada, US, RoW
Glofitamab, RO7082859, Obinutuzumab (G), Gazyva, Rituximab (R), Rituxan, Tocilizumab, Actemra, Cyclophosphamide, Doxorubicin, Vincristine, Oncovin, Prednisone, Polatuzumab vedotin
Hoffmann-La Roche
B-Cell Lymphoma, Non-Hodgkin Lymphoma
10/24
10/24
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
02/25
02/26
BP41072, NCT04077723: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Recruiting
1
498
Europe, US, RoW
RO7227166, A CD19 Targeted 4-1BB Ligand, Obinutuzumab, Gpt, RO5072759, Gazyva, Gazyvaro, Glofitamab, CD20-TCB, RO7082859, Tocilizumab, Actemra, RoActemra
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
03/25
03/25
NCT03432741: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Suspended
1
39
US
Belinostat, Beleodaq, PXD 101, PXD101, Carfilzomib, Kyprolis, PR-171, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera
Mayo Clinic, National Cancer Institute (NCI)
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
04/25
05/26
BP43131, NCT05219513: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Recruiting
1
200
Europe, US, RoW
RO7443904, Glofitamab, RO7082859, Obinutuzumab, Tocilizumab, Actemra
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
04/25
04/25
SAVE, NCT04843904: Safe Accelerated Venetoclax Escalation in CLL

Recruiting
1
40
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Rituximab, Rituxan
Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/25
06/30
NCT05653271: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Recruiting
1
42
US, RoW
Cyclophosphamide, Fludarabine, ACE1831, Obinutuzumab
Acepodia Biotech, Inc.
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma
09/25
09/27
NCT04599634: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Active, not recruiting
1
1
US
Obinutuzumab, Venetoclax, Magrolimab
National Cancer Institute (NCI)
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
03/24
02/27
NCT05943496: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Recruiting
1
25
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Questionnaire Administration, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574
OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation
Chronic Lymphocytic Leukemia
01/26
01/27
CO43805, NCT05169515: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Recruiting
1
121
Europe, US, RoW
SC Mosunetuzumab, RO7030816, IV Glofitamab, RO7082859, CC-220, CC-99282, Obinutuzumab, RO5072759, Tocilizumab, RO4877533
Hoffmann-La Roche
Non-Hodgkin Lymphoma
07/26
07/28

Download Options